Back to top

Is Pfizer (PFE) Stock Outpacing Its Medical Peers This Year?

Read MoreHide Full Article

Investors focused on the Medical space have likely heard of Pfizer (PFE - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of PFE and the rest of the Medical group's stocks.

Pfizer is one of 756 companies in the Medical group. The Medical group currently sits at #4 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.

The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. PFE is currently sporting a Zacks Rank of #2 (Buy).

Over the past three months, the Zacks Consensus Estimate for PFE's full-year earnings has moved 1.05% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.

According to our latest data, PFE has moved about 22.23% on a year-to-date basis. In comparison, Medical companies have returned an average of 11.82%. This means that Pfizer is performing better than its sector in terms of year-to-date returns.

Looking more specifically, PFE belongs to the Large Cap Pharmaceuticals industry, which includes 14 individual stocks and currently sits at #44 in the Zacks Industry Rank. On average, stocks in this group have gained 9.75% this year, meaning that PFE is performing better in terms of year-to-date returns.

PFE will likely be looking to continue its solid performance, so investors interested Medical stocks should continue to pay close attention to the company.




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Pfizer Inc. (PFE) - free report >>

More from Zacks Tale of the Tape

You May Like